Impact of Skeletal Muscle Quality and Loss on the Outcome of Liver Transplantation
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Liver Transplantation, Muscle Loss, Muscle Quality. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
CT imaging-based skeletal muscle assessment has been found to predict the outcomes of many diseases. Previous evidence revealed that pre-transplant muscle quality and post-transplant muscle loss were associated with transplant outcomes. However, there is no prospective study supporting the aforementioned conclusions. This study aims to prospectively include liver transplant patients from multiple transplant centers, collecting their pre-transplant CT images as well as post-transplant CT images at specific time points. The objective is to further explore and clarify the correlation between skeletal muscle assessment and the prognosis of liver transplant patients. The goal is to provide guidance for peri-transplant health monitoring and disease intervention for liver transplant patients.
Primary outcome measures
- Postoperative mortality [Time frame: 2024.1.1-2027.1.1]
- Postoperative recurrence of liver cancer [Time frame: 2024.1.1-2027.1.1]
Eligibility criteria
Inclusion criteria
- Adult patients undergoing deceased donor liver transplantation (DDLT) for the first time
Exclusion criteria
- Pediatric transplants
- Presence of portal vein tumor thrombus according to imageing before transplantation
- Presence of macrovascular invasion according to imageing before transplantation
- Re-transplants
- Multi-organ transplants
- Patients who died within 30 days after transplantation
- Patients diagnosed with skeletal muscle diseases (e.g. muscle atrophy)
- Patients with serious medical conditions such as heart failure, persistent infection, and renal insufficiency.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06188273 · CT2023-ZJU-OBS3